Gallium Dotatate
Carcinoid
University of Alabama at BirminghamEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Carcinoid cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Paltusotine Crinetics Pharmaceuticals Inc. | Phase 3 | BB |
Oxodotreotide RayzeBio, Inc. | Phase 3 | BB |
Everolimus RayzeBio, Inc. | Phase 3 | B |
Lanreotide RayzeBio, Inc. | Phase 3 | B |
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | B |
View all 30 →
Same molecule, other indications
Gallium Dotatate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →